IBD: Higher concentrations of infliximab can improve blood and fecal neutrophil biomarkers in patients with Crohn's disease

Endoscopic evaluation is still the gold standard for monitoring the treatment response of patients with Crohn's disease (CD).
However, frequent endoscopy for assessment of disease severity will increase the economic and physical burden of patients
.
Therefore, there is a growing need for biomarkers to replace invasive detection because it can avoid frequent invasive surgery

Researchers in the Pediatric Crohn's Disease (CD) cohort study analyzed the differences in FCP, LCT, and nCD64 levels of patients before and after induction of IFX therapy

In 56 CD patients, ROC curve analysis showed that when LCT <8.
06 (area under the receiver's operating characteristics [AUROC], 0.
934, P <0.
001) and nCD64 <6.
12 (AUROC, 0.
76, P = 0.
02) are the ideal first The cut-off value of FCP biomarker remission at 14 weeks
.
The trough concentration of the drug during IFX induction therapy>9.

Figure: Higher drug concentration of infliximab can improve blood and fecal neutrophil biomarkers in patients with Crohn's disease

This study determined the cut-off values ​​of neutrophil fecal and blood biomarkers for the biochemical remission after IFX induction therapy and the trough concentration level of therapeutic drugs, which can provide some help for clinical treatment
.

Original source:

Ruben J Colman.